Marie Bosslett, Assistant Editor

This innovative approach to multimodal aesthetics care was announced at IMCAS World Congress 2025.

“The Big See” campaign and the Seal of Recommendation program are just 2 examples of initiatives led by the Skin Cancer Foundation.

85% of Chinese PN patients saw a PP-NRS improvement of ≥ 4 points after 12 weeks of treatment.

The Foundation’s extensive library includes brochures, magazines, and posters to promote education among dermatologists and patients.

Investigators observed lowered MASI and PGA scores in the side of the face treated with BoNT-A.

One of the Foundation’s top initiatives is its mobile skin cancer screening program, “Destination Healthy Skin.”

A new review highlights overall allergen rates among children in the United States between 2010 and 2024.

In case you missed it, this week we had news about the link between psoriasis and dementia, the future of urticaria treatment, VP-315's positive results in basal cell carcinoma, and more.

More luminous skin with reduced fine lines and hyperpigmentation was seen as early as 2 weeks.

Compared to minoxidil alone, the combination therapy saw no significant differences in hair count and diameter.

Combining synchronized radiofrequency with high intensity facial electrical stimulation led to firmer, smoother, and more lifted skin.

According to a phase 3 study, the omalizumab biosimilar saw comparable results with a good safety profile.

These efficacy results and safety profile confirm what was observed in phase 1 study.

Researchers analyzed stratum corneum hydration and transepidermal water loss across 15 regions of the skin.

Patients saw notable improvements in skin hydration, firmness, elasticity, and radiance after 4 and 12 weeks.

Although HA and other methods are safe, more reliable data is needed to determine which is most effective.

When compared to the placebo, hair growth and quality significantly improved by day 180.

In a real-world study, 10 children with generalized pustular psoriasis saw sustained improvements up to 160 weeks.

In case you missed it, this week we had news about AIs and CNNs for early melanoma detection, OCT Technology for vitiligo imaging, UCB’s 320mg single-injection bimekizumab, and more.

The addition of a dermocosmetic cleanser and moisturizer also lessened the adverse events commonly associated with retinoid use.

According to a systemic review, both topical and oral antifungal therapies are insufficient for managing the disease.

The use of a pre-gel and cleansing lotion regimen saw an improvement rate of 80% for patients with seborrheic dermatitis.

Patients saw a 15.8% significant decrease in Post Acne Hyperpigmentation Index score after just 84 days.

Investigators found strong correlations between certain eating habits, BMI, psychoemotional status, and SD occurrence.

Although more evidence is needed, CNNs could potentially be most effective in diagnosing patients with vitiligo.

“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.

Disease severity improved from severe to mild after just 6 weeks of twice daily dosage.

Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.

The new partnership will advance the commercialization of small molecule oral STAT6 for patients around the world.

In case you missed it, this week we had news about phase 2b enrollment for VYNE’s vitiligo gel, the impact of anti-inflammatory moisturizers for AD, the newly FDA-approved DermiSphere hDRT, and more.